Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiki Niimi

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Bioscience Trends|April 21, 2022
Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting databaseKenichiro Sato, Yoshiki Niimi, Tatsuo Mano, et al.
Biomedicines|August 29, 2024
Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer's Disease TreatmentKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|September 13, 2024
Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive ValueKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluationAmbre Mounié, Kenichiro Sato, Saki Nakashima, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 7, 2021
Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting databaseKenichiro Sato, Tatsuo Mano, Yoshiki Niimi, et al.
Journal of Alzheimer'S Disease Reports|June 11, 2025
Audio review as a measure of quality assurance and control of cognitive assessments in Alzheimer's disease studies: An experience from Japanese Trial-Ready Cohort StudyKenichiro Sato, Ryoko Ihara, Yoshiki Niimi, et al.
Journal of Alzheimer'S Disease : JAD|June 30, 2025
Effect of corrections for renal function on plasma phosphorylated tau performance for Alzheimer's diseaseKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Bioscience Trends|July 15, 2021
The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims databaseKenichiro Sato, Tatsuo Mano, Yoshiki Niimi, et al.
Frontiers in Dementia|July 31, 2024
<i>APOE</i>-ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapyKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Fujita Medical Journal|February 3, 2022
Fatigue evaluated using the 16-item Parkinson Fatigue Scale (PFS-16) predicts Parkinson's disease prognosisYoshiki Niimi, Sayuri Shima, Yasuaki Mizutani, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Bioscience Trends|April 21, 2022
Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting databaseKenichiro Sato, Yoshiki Niimi, Tatsuo Mano, et al.
Biomedicines|August 29, 2024
Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer's Disease TreatmentKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|September 13, 2024
Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive ValueKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluationAmbre Mounié, Kenichiro Sato, Saki Nakashima, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 7, 2021
Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting databaseKenichiro Sato, Tatsuo Mano, Yoshiki Niimi, et al.
Journal of Alzheimer'S Disease Reports|June 11, 2025
Audio review as a measure of quality assurance and control of cognitive assessments in Alzheimer's disease studies: An experience from Japanese Trial-Ready Cohort StudyKenichiro Sato, Ryoko Ihara, Yoshiki Niimi, et al.
Journal of Alzheimer'S Disease : JAD|June 30, 2025
Effect of corrections for renal function on plasma phosphorylated tau performance for Alzheimer's diseaseKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Bioscience Trends|July 15, 2021
The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims databaseKenichiro Sato, Tatsuo Mano, Yoshiki Niimi, et al.
Frontiers in Dementia|July 31, 2024
<i>APOE</i>-ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapyKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Fujita Medical Journal|February 3, 2022
Fatigue evaluated using the 16-item Parkinson Fatigue Scale (PFS-16) predicts Parkinson's disease prognosisYoshiki Niimi, Sayuri Shima, Yasuaki Mizutani, et al.
Pageof 8